In a commentary published in the University of Ottawa nursing journal Aporia, Paula Caplan writes about how Allen Frances and two other academic psychiatrists were paid by Johnson & Johnson in the late 1990s to write a practice guideline that identified Risperdal, the company's new atypical antipsychotic, as a preferred treatment for schizophrenia.
This fact was first revealed in a 2010 report by David Rothman, who was hired as an expert witness by the state of Texas when it sued J&J for Medicaid fraud in its marketing of Risperdal. Frances, who directed the task force that authored DSM-IV, has written a response to Caplan's article on Huffington Post.
Caplan, Paula. Diagnosisgate: Conflict of Interest at the Top of the Psychiatric Apparatus. Aporia. Volume 7, Issue 1. (Full text)